Privacyvoorkeur

MEDtalks houdt u graag op de hoogte van de laatste ontwikkelingen op uw interessegebied. Kies hieronder of u op de hoogte gehouden wilt blijven van de nieuwste programma's en nascholingen binnen uw interessegebieden. Klik hier voor meer informatie.


ESMO 2021 journaal | Mammacarcinoom

42 min.

Dr. Marleen Kok en dr. Willemien Menke bediscussiëren samen met presentator Inge Diepman het belangrijkste ESMO-nieuws op het gebied van mammacarcinoom.

De volgende abstracts komen aan bod:

  1. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a randomised, phase 3 trial of the Gruppo Italiano Mammella.
  2. POSEIDON randomized phase II trial: tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)
  3. Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
  4. First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies.
  5. Individual patient data Meta-Analysis of 5 Non-Inferiority RCTs of Reduced Duration single agent adjuvant Trastuzumab in the treatment of HER2 positive Early Breast Cancer
  6. Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized Phase 3 DESTINY-Breast03 Study
  7. Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
  8. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized Phase 3 trial
  9. KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC (ESMO Virtual plenary juli 2021)
  10. Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
  11. KEYNOTE-355: Final results from a randomized, double-blind phase 3 study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
     

Bekijk hier het volledige overzicht van onze ESMO 2021 journaals en interviews.

Laatst bewerkt: 20-12-2023

  • Sponsoren

    Dit programma komt onafhankelijk tot stand en wordt financieel mogelijk gemaakt door